Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announced the first patients were enrolled in Esprit, a global Phase 2 clinical trial evaluating S-606001, an investigational drug for the treatment of late-onset Pompe disease (LOPD).
Shionogi Announces First Patients Enrolled in GlobalPhase 2 Clinical Trial in Adults with Late-Onset Pompe Disease... S-606001 is currently under investigation in clinical trials for the treatment of late-onset Pompe disease.
“The totality of these data show compelling clinical evidence that ABX1100 may offer a substantial benefit to people with late-onset Pompe disease,” said Purnanand Sarma, Ph.D., chief executive officer of Aro Biotherapeutics.
Bahrain said Sunday that its air defenses intercepted and destroyed 125 missiles and 211 drones from Iran since Feb. 28 ... Hostilities have escalated since Feb ... .
At least 3,195 people have been injured in Iranian attacks since the start of the Israeli-US war against Iran late last month, the Health Ministry said Sunday ... 28 ... Hostilities have escalated since Feb ... *Writing by Rania Abushamala in Istanbul .